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Introduction
Autoinflammatory diseases cause systemic inflammation
which can result in damage to multiple organs. Organ
damage can occur before the start of therapy, or when
patients experience ongoing inflammation. A validated
instrument to measure damage is essential to quantify
damage in individual patients, and to compare disease
outcomes in clinical studies. At this moment, there is
no such instrument. In the context of the RaDiCEA pro-
ject, a common damage index for Familial Mediterra-
nean Fever (FMF), Cryopyrin Associated Periodic
Syndromes (CAPS), Tumor Necrosis Factor Receptor
Associated Periodic Syndrome (TRAPS) and Mevalonate
Kinase Deficiency (MKD) will be developed.
Objectives
To develop an autoinflammatory disease damage index
(ADDI).
Methods
The ADDI will be developed by consensus building based
on the Delphi method. The top 40 enrollers of autoinflam-
matory disease patients in the Eurofever registry, were
invited to take part in the expert group, as well as nine
important experts from the Americas. A systematic litera-
ture search for damage in autoinflammatory diseases was
performed to establish possible damage items. These items
were rated by the experts in an online survey. Experts
could also provide new damage items that were not found
in the literature. Furthermore, in close collaboration with
the Autoinflammatory Alliance, twenty-two patients and
parents of patients were asked to rate damage items from
the literature and to suggest other damage items. Based on
the comments and suggestions of experts and patients, the
damage items will be adapted; multiple rounds of online
surveys will be performed to reach consensus. The final
damage index will be determined in a face-to-face consen-
sus meeting.
Results
Fifty-seven possible damage items from the literature were
selected for the online survey. Forty of forty-nine experts
completed the first round of the online survey. Based on
the first round, five items were excluded and seventeen
new items were suggested by experts. Twenty-one patients
completed the online survey. Patients suggested nineteen
new items, for example learning disabilities, chronic fati-
gue and speech development delay. The second round will
be adapted based on these results.
Conclusion
An instrument to measure damage caused by autoinflam-
matory diseases (ADDI) will be developed based on the
Delphi consensus procedure, including online surveys and
a consensus meeting. Patients fulfil a significant role in
this process.
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